---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-019478"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2026-06-04T12:30:11+00:00"
generated_at: "2026-06-04T12:36:24.423425+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Veru enters clinical supply deal with Novo Nordisk for Phase 2b combo study of enobosarm + Wegovy

## Summary
- Veru sponsors Phase 2b PLATEAU study testing enobosarm + Wegovy in older adults with obesity on GLP-1 therapy.
- Novo Nordisk supplies Wegovy at no cost; Veru retains full global rights to enobosarm.
- Veru grants Novo Nordisk right of first negotiation if Veru develops enobosarm combo with any Novo GLP-1 product.
- Veru provides trial design and safety data insights; no financial terms disclosed.

## SEC filing metadata
- accession: 0001437749-26-019478
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2026-06-04T12:30:11+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000143774926019478/0001437749-26-019478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-019478
- JSON: https://secwatch.observer/filing/0001437749-26-019478.json
- Plain text: https://secwatch.observer/filing/0001437749-26-019478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.